How tirzepatide affects lipolysis and fat metabolism

What the trial data tells us about fat loss on tirzepatide

The clearest picture comes from SURMOUNT-1, a 72-week randomised controlled trial published in the New England Journal of Medicine, which enrolled 2,539 adults with obesity but without type 2 diabetes. At the 15mg dose, participants lost an average of around 20–21% of body weight. That figure is not simply fluid or lean tissue; imaging substudies in the tirzepatide clinical programme consistently show the majority of mass lost is adipose (fat) tissue. NICE's appraisal of tirzepatide, TA1026, drew on this and wider evidence to recommend it for NHS use, noting results that outpaced previously available weight-loss medicines.

Weight loss at that scale requires sustained lipolysis: fat cells releasing triglycerides into the bloodstream, which are then oxidised for energy. Tirzepatide does not trigger lipolysis directly the way adrenaline does during intense exercise. Instead, it creates the conditions for it, chiefly by substantially reducing caloric intake through appetite suppression, so the body progressively draws on fat reserves to meet its energy needs.

The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. If you want to understand how this medicine works in detail, our tirzepatide guide covers the mechanism, dosing and clinical background clearly.

Dual-receptor activation and what it means for fat metabolism

GLP-1 receptor agonists have been studied for years. What makes tirzepatide different is the addition of GIP receptor activation, a pathway that, until recently, was considered less relevant to weight management. It turns out GIP receptors are expressed in adipose tissue itself, and activation appears to influence how fat cells handle lipids. Early mechanistic research suggests GIP signalling may reduce fat cell inflammation and alter the local hormonal environment in adipose depots, making them more responsive to energy-deficit signals.

The GLP-1 component handles gastric emptying (slowing the rate at which food leaves the stomach, extending fullness) and acts centrally to reduce appetite. Together, the two pathways produce a caloric deficit that is larger and more sustained than either achieves alone. It is that deficit, maintained week after week, that drives the lipolysis reflected in the trial weight-loss figures.

Lean mass preservation matters here too. When the body breaks down fat rapidly, there is a risk of also losing muscle. The tirzepatide trial data suggest body-composition changes are predominantly fat loss, though the NHS patient information for tirzepatide and the prescribing guidance both emphasise pairing treatment with adequate protein intake and physical activity to support lean tissue.

Practical implications: lipolysis, diet and how the two interact on treatment

Understanding that tirzepatide accelerates fat breakdown by reducing intake (rather than by directly stimulating fat-cell enzymes) has a practical consequence. If someone on treatment significantly restricts carbohydrate or total calories beyond what appetite naturally dictates, they may deepen the energy deficit further, but they may also risk accelerating muscle loss and electrolyte shifts. Getting the balance right is exactly the kind of individual judgement a prescriber reviews at each stage of treatment.

A detail worth knowing: your pen lives in the fridge, ideally at 2–8°C, and our tirzepatide storage and handling page sets out the limited room-temperature window if you need to carry it, along with the patient information leaflet as the definitive source for storage specifics. Routine matters because consistent weekly dosing is what keeps the hormonal environment stable enough to sustain the metabolic changes that underpin fat loss.

Questions about what the pooled evidence says across tirzepatide trials and about rare muscular side effects sometimes come up in the context of fat metabolism and exercise. Both are worth reading if you are thinking about what training alongside tirzepatide looks like. For a full overview of how the medicine works and what it is licensed for, the Mounjaro overview covers the ground clearly.

If you are considering treatment, the starting point is a clinical assessment. Our prescribers at nume review each consultation personally, a real clinician reads your answers the same day, not a piece of software. Cost context, including what a private prescription for tirzepatide involves, is covered on our Mounjaro price comparison page. When you are ready, you can check your eligibility and start a free consultation.